Skip to main content
. 2016 Dec 13;9:7503–7513. doi: 10.2147/OTT.S115268

Figure 7.

Figure 7

Progression-free survival based on CTC kinetics and the treatment with anti-VEGF monoclonal antibody.

Notes: Continuous line: patients treated with anti-VEGF with favorable kinetics (CTC1+ and CTC2−). Dotted line: patients treated with anti-VEGF with unfavorable kinetics (CTC1− and CTC2+; P=0.007).

Abbreviation: CTC, circulating tumor cell.